The FDA Just Shut Down 503B Compounded Semaglutide | DOWNSIZED LIVE!

Welcome to Downsized Live. We’ve got a big night ahead, and we’re starting with a major update that impacts all of us—whether you’re currently using a GLP-1 or thinking about starting. Then we’ll jump into your questions, celebrate your wins, and keep building this community of people who are treating the disease of obesity together. Here’s what just happened: A federal judge has ruled in favor of the FDA and Novo Nordisk—officially removing semaglutide from the drug shortage list and ending 503B compounding. If you’ve been relying on compounded versions of Wegovy or Ozempic, your access may be in jeopardy. We break down the full case, share direct quotes from the ruling, explain why the court sided with the FDA, and talk about the sudden $199 Wegovy cash offer Novo launched for compounded patients—set to expire June 30. We’re also calling on Novo to do the right thing. Stop the legal attacks. Make $199 permanent. And lead with access, not just exclusivity. This episode includes: Full court ruling summary and analysis The judge’s words on why OFA lost What happens next for compounded semaglutide and tirzepatide Novo’s $199 Wegovy move—and why it matters Our weight loss stories (over 150 pounds lost combined) Live Q&A and community wins — DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store Join CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... DOWNSIZED WEBSITE: https://thedownsized.org/ FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/